Pantazol Injection (Pantoprazole Sodium Sesquihydrate)

Adult dosage

When oral administration of pantoprazole is inappropriate, dissolve 1 vial of this medicine (equivalent to 40 mg of pantoprazole) in 10 mL of normal saline for injection and administer by direct intravenous injection, or mix this solution with 100 mL of normal saline for injection or 5 % dextrose solution and administer intravenously over 2∼15 minutes. As soon as oral administration becomes possible, discontinue intravenous pantoprazole and replace it with oral pantoprazole 40 mg. 1. Duodenal ulcer, gastric ulcer, moderate to severe reflux esophagitis Administer 1 vial of this medicine (equivalent to 40 mg of pantoprazole) intravenously once daily. 2. Zollinger-Ellison syndrome and other pathological hypersecretory conditions - Start with an initial dose of 80 mg per day, then increase or decrease the dose according to measurements of gastric acid secretion. - For doses of 80 mg or more, administer in 2 divided doses per day. - The dose may be temporarily increased to 160 mg or more, but only to the extent needed to achieve adequate acid control. - If rapid acid control is needed, an initial dose of 2 × 80 mg reduced acid output to the target range (< 10 mEq/h) within one hour in most patients. For patients with severe hepatic impairment, the daily dose should be reduced to 20 mg of pantoprazole. For elderly patients or patients with renal impairment, the daily dose should not exceed 40 mg of pantoprazole.

This medication should not be administered to certain patients. Patients who are hypersensitive to this drug or its components, or who have experienced such reactions in the past, should not use this drug. Furthermore, patients currently taking Atazanavir, Nelfinavir, or Rilpivirine should not use this drug. When using this drug, various adverse reactions may occur. For example, blood-related issues, gastrointestinal symptoms, respiratory symptoms, injection site reactions, liver function abnormalities, immune system reactions, neurological symptoms, and skin reactions have been reported. Care is required as there may be severe skin conditions or hypersensitivity reactions such as anaphylactic shock. This drug may alleviate malignant tumor symptoms or delay diagnosis; therefore, if symptoms suspected of malignancy coexist with gastric ulcers, it must be confirmed that they are not malignant. Regular monitoring is needed during long-term use, and dosage should be reduced in patients with severe liver dysfunction. As a proton pump inhibitor, long-term use may increase the risk of fractures and cause electrolyte abnormalities such as hypomagnesemia. In such cases, magnesium supplementation or drug discontinuation may be necessary, and blood magnesium levels should be monitored regularly. Additionally, this drug inhibits gastric acid secretion, which can increase the risk of bacterial infections in the intestine; therefore, if diarrhea persists, medical consultation is necessary. Dizziness or visual disturbances may occur, necessitating caution when driving or operating machinery. There is a risk of toxicity when used in combination with drugs such as Methotrexate, so healthcare providers must be informed. It is advisable to avoid use in the first three months of pregnancy, and nursing women should also avoid this drug. Experience in using this drug in children and adolescents under 18 years is limited, so it is not recommended. No specific safety differences have been reported in the elderly, but it should be used with caution. No specific symptoms of overdose are known, but if symptoms occur, immediate medical attention is required and symptomatic treatment may be necessary. This medication must be dissolved in saline injection solution or glucose solution before administration, and the prepared solution should be used within 12 hours. Care should be taken to store the solution below 25°C, and products that are discolored or cloudy should be discarded. Lastly, caution is advised for long-term use as animal experiments have shown associations with specific tumor occurrences.

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, upper abdominal pain, diarrhea, constipation, abdominal distension, dyspepsia, gastric polyp, nausea, vomiting, dry mouth, rhinitis, injection site reaction, thrombophlebitis at the injection site, fever, peripheral edema, pyrexia, increased bilirubin, liver failure, jaundice, hepatocellular damage, elevated liver enzyme levels, arthralgia, myalgia, rhabdomyolysis, bone fracture, headache, dizziness, visual disturbances, altered taste, insomnia, sleep disorders, depression, hallucinations, disorientation, confusion, interstitial nephritis, pruritus, skin rash, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, photosensitivity reaction, gynecomastia, hyperlipidemia, increased lipids, weight changes, hyponatremia, hypomagnesemia, elevated CK, anterior ischemic optic neuropathy, pancreatitis, confusion, reduced activity, speech disorders, increased saliva, vertigo, tinnitus, hypocalcemia, hypokalemia, Clostridium difficile-associated diarrhea, paresthesia, DRESS syndrome, microscopic colitis, systemic lupus erythematosus, cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, arthralgia, hematopoietic depression

This medication may be sensitive to light, so it should be stored in a tightly sealed container that blocks light. Additionally, it is important to store it at a cool temperature below 25 degrees to maintain its effectiveness.

Appearance

A colorless and transparent vial containing a white to almost white dry powder

Package unit

10 vials/box